Articles tagged with Antiretrovirals
Young people with HIV who receive injections every eight weeks manage their condition better than those taking daily tablets, according to a study published in The Lancet. The injections suppressed the virus more effectively, with only 1% of participants experiencing viral rebound, compared to 6% on daily tablets.
Weill Cornell Medicine and Rutgers Health have received a four-year, $3 million grant to build a research center focused on HIV-associated brain injury. The center will help investigators access shared molecular and computational tools to define the mechanisms of brain injury and identify new therapeutic opportunities.
The five-year Brain-FRAMe program aims to improve clinical care and brain health for people with HIV and active methamphetamine use disorder through innovative, multidisciplinary treatment approaches. The program investigates the combined efficacy of long-acting injectable ART and medication for addiction treatment.
Researchers at Oregon Health & Science University have made a groundbreaking discovery in animal models that a one-time treatment regimen can permanently clear HIV from newborns. The study's findings have the potential to advance quickly to human clinical trials, offering new hope for millions of people worldwide who require lifelong t...
A noninferiority randomized clinical trial found that an alternative first-line regimen containing doravirine, lamivudine, and tenofovir disoproxil fumarate produced less weight gain than a combination of dolutegravir, emtricitabine, and tenofovir alafenamide. The regimen was noninferior for viral suppression at 48 weeks.
A new study reveals two specific genes that act like security locks to keep the virus asleep in some individuals who naturally control HIV even after stopping therapy. Metformin, a common diabetes drug, can activate one of these locks to keep the virus in its dormant state.
A new tool, HIV-seq, has been developed to profile rare HIV-infected cells from people with HIV. The tool has recovered and analyzed more HIV-infected cells and higher numbers of HIV RNA within those infected cells. The study has identified key differences in people's HIV-infected cells before versus after starting antiretroviral therapy.
A new combination therapy approach enabled seven out of ten participants to keep the virus at low levels for many months after going off antiretroviral therapy. The results suggest a possible cure for HIV and offer a proof of concept that this approach could work.
Experts Gregory Folkers and Anthony Fauci highlight promising therapeutic developments in antiretroviral treatments for HIV/AIDS. The authors emphasize the need for continued research to end the AIDS epidemic, citing recent advances as unfinished business.
A study from the Ragon Institute of Mass General Brigham, MIT and Harvard found that immune cells called CD8+ T cells play a crucial role in controlling HIV. Researchers discovered that having these CD8+ T cell features before treatment was most important for achieving remission.
A new study from Texas Biomedical Research Institute found that low-dose THC significantly reduced side effects and inflammation caused by HIV and antiretroviral therapy. The treatment also increased serotonin levels, lowered cholesterol and toxic bile acids, and improved cardiovascular health.
The US Department of Health and Human Services Panel has recommended moderate-intensity statin therapy as the primary prevention among adults with HIV aged 40-75 years with low to intermediate 10-year atherosclerotic cardiovascular disease (ASCVD) risk. For those with a 10-year ASCVD risk score of 5% or higher, statin therapy is strong...
A new study found that eight times more American young adults now take HIV-prevention medication than a decade ago, but inconsistent use and barriers persist. PrEP can reduce the chances of acquiring HIV by 99%, emphasizing the need for healthcare providers and public health agencies to promote consistent use among high-risk patients.
A new study conducted by Medical University of South Carolina shows that long-acting injectable antiretroviral therapy for persons living with HIV can be administered safely and effectively at home. Patient satisfaction scores were high for both groups, and no serious safety issues were observed.
A new study by NYU researchers found that adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV. The study sheds light on the significant burden of dementia among people living with HIV in resource-poor settings.
A new study by researchers at UCSF has found that long-acting injectable treatments can be transformative for patients who struggle to take daily HIV pills, resulting in undetectable viral loads and improved health outcomes. The treatment approach could help stop the spread of HIV by keeping more patients from being infectious.
The updated recommendations provide a comprehensive framework for healthcare professionals to deliver better care and move closer to ending the HIV epidemic. The guidelines emphasize tailored antiretroviral therapy, effective HIV prevention strategies like pre-exposure prophylaxis, and comprehensive care for people living with HIV.
The 2024 guidelines provide updated recommendations for treating and preventing HIV in adults, highlighting new approaches to address disparities and inequities in access to care. These tools aim to help end the HIV epidemic by improving treatment outcomes and reducing transmission rates.
A new IHME study reveals significant progress in the global fight against HIV/AIDS, with sub-Saharan Africa leading the way in cutting new HIV infections and deaths. However, the world is not on track to meet UNAIDS 2030 targets, with a quarter of people living with HIV not receiving treatment.
A $3.96 million grant will support the development of a monitoring device and data-processing algorithm to guide combination therapy design against multidrug-resistant bacteria. The goal is to overcome bacterial defenses and combat the emergence of resistance.
A hospital-based study found depression highly prevalent among people living with HIV (44.9%) in a Nigerian university teaching hospital. Sociodemographic factors such as male gender, formal employment, and moderate income levels were associated with reduced odds of depression.
Researchers at Texas Biomedical Institute have developed a TB therapy that does not interfere with combined antiretroviral therapy (cART) in patients with HIV. The host-directed therapy blocks an immune system protein and has shown improved control of TB when used with antibiotics.
Researchers used a dual blockade of IL-10 and PD-1 to control SIV viral rebound after treatment interruption. The approach led to significant reduction in viral loads and reservoirs, showing promise for HIV treatment strategies.
Researchers at the University of Montreal Hospital Research Centre have discovered that metformin can help deplete and eliminate viral reservoirs in people living with HIV. Metformin inhibits the mTOR molecule, slowing down HIV replication and reducing chronic inflammation.
A new drug has shown promise in clearing HIV from the brain by targeting infected cells and reducing viral load. The treatment, BLZ945, successfully cleared the virus from brain tissue, providing a potential new avenue for HIV treatment.
A study found that providing resistance tests for HIV patients has no significant impact on treatment outcomes. Instead, daily medication adherence is key to improving treatment success. The researchers suggest prioritizing resources for programs focusing on children and adolescents' specific needs.
Scientists are conducting a clinical trial to explore the use of anti-retroviral medications Ritonavir and Lopinavir as a potential treatment for brain tumors in patients with Neurofibromatosis 2. The study aims to determine if these drugs can help reduce tumor growth and survival in NF2 patients.
A new implementation programme highlights challenges of locating and re-engaging former prisoners and individuals living with HIV who drop out of care. The study found that retaining these patients in care is crucial to end the global HIV epidemic.
A new nanofluidic implant has been shown to deliver an HIV drug with increased potency compared to existing oral medications, providing a potential breakthrough in addressing treatment nonadherence. The device is intended for long-term controlled release and avoids repeated systemic treatment, which can lead to adverse side effects.
A study published in JAMA found that three months of social worker follow-up support improved HIV clinic attendance and antiretroviral therapy initiation, but did not reduce mortality after one year. The intervention, known as Daraja, was highly effective at addressing barriers to care such as stigma and lack of social support.
Researchers have discovered how lenacapavir disrupts the HIV life cycle by fortifying the capsid and making it brittle. This leads to a premature breakage of the capsid, exposing the viral genetic material to the host cell cytoplasm.
A new clinical trial demonstrates a small reduction in the latent reservoir of HIV-infected cells using a combination of vorinostat and immunotherapy. While the results are promising, further research is needed to create more effective approaches to flush out the virus and attack it when it emerges from latency.
A new study using an animal model has identified a window of opportunity for early treatment to promote long-term control and remission of HIV infection. Starting treatment four weeks after infection promotes viral control after discontinuation of treatment, highlighting the importance of early diagnosis and treatment.
Researchers from Brigham and Women's Hospital found that anti-HIV drugs can prevent liver abscess formation during Escherichia coli infections by blocking reverse transcription. This mechanism could lead to a new way of treating and preventing deleterious consequences following bloodstream infections.
A new study will analyze electronic health records to identify facilitators and barriers of successful pediatric-to-adult HIV care transitions among youth in South Carolina. The research aims to develop guidance to improve systems and protocols for vulnerable populations.
The TAF/EVG fast-dissolving vaginal insert is being evaluated in a Phase 1 study to determine its safety and user acceptability. The study aims to assess the product's effectiveness as an on-demand HIV prevention method for women, particularly those who do not want or can't use daily PrEP or long-acting products.
Researchers have discovered that an HIV drug, cobicistat, can stop many coronavirus diseases when given to infected cells at the right concentration. The findings could strengthen antiviral treatments against current and future outbreaks of coronaviruses.
New HIV diagnoses rose by 31% in the EU/EEA in 2022, with migrants accounting for 49% of cases. Ukrainian refugees made up a significant proportion of new diagnoses, with women disproportionately affected. The increase highlights the need for tailored early testing and treatment approaches to address this growing public health threat.
The USPSTF recommends prescribing preexposure prophylaxis using effective antiretroviral therapy to individuals at high risk of HIV acquisition. This strategy aims to decrease the risk of acquiring HIV, particularly among the estimated 1.2 million people living with HIV in the US.
Researchers have identified a family of broadly neutralizing antibodies targeting the HIV-1 envelope protein, which may contribute to long-term remission from infection. These antibodies were found to induce the elimination of infected cells and impose a selective pressure on the virus, paving the way for new therapeutic approaches.
A new molecular compound has been identified that can activate latent HIV-1 in cells, showing promise for HIV treatments. Researchers found that this compound, YSE028, can reactivate latently infected cells and induce cell death, potentially leading to a complete cure for HIV.
Researchers identified a molecule that allows HIV to hide in reservoirs within CD4+ T lymphocytes. The aryl hydrocarbon receptor protein plays a crucial role in viral latency and has shown potential as a good therapeutic target.
Researchers developed a new approach to evaluate HIV infection through the entire male genital tract, showing that productive HIV infection occurs in all organs of the male genital tract. Antiretroviral treatment can suppress HIV production and prevent penile HIV infection by using pre-exposure prophylaxis with an antiviral drug.
Scientists at Medical College of Georgia are investigating the impact of HIV treatment on bone and muscle aging. They found that common antiretroviral cocktails can accelerate aging by about a decade, leading to increased inflammation and oxidative stress in bone marrow stem cells.
A video-based smoking cessation program developed by a University of Massachusetts Amherst researcher has helped nearly 40% of HIV-positive smokers in Nepal quit tobacco. The program, which includes 11 video sessions and is accessible via smartphone app, was found to be highly effective in promoting abstinence among participants.
Researchers at Temple University and the University of Nebraska Medical Center developed a novel dual gene-editing approach that can effectively eliminate HIV infection. The therapy targets both HIV-1, the virus responsible for AIDS, and CCR5, a co-receptor that facilitates viral entry into cells.
A recent study found that the mitochondrial antioxidant MitoQ can reverse the detrimental effects of HIV and antiretroviral therapy on organs such as the brain, heart, and liver. The researchers used humanized mice infected with HIV and treated them with MitoQ for three months.
After a stem cell transplant from a donor with the CCR5-delta 32 mutation, a man was able to stop his antiretroviral treatment without viral resurgence. Four years later, no HIV virus could be detected in his body, indicating probable cure. This case joins two previous reported cases and offers further proof that HIV can be cured.
Researchers found dapivirine levels in breast milk to be very low, posing no safety concerns. The study supports the inclusion of breastfeeding populations in global guidelines for the use of the dapivirine vaginal ring for HIV prevention.
A new study has confirmed that people living with HIV who switch from efavirenz to dolutegravir may gain more weight and have a higher risk of developing high blood pressure. The study found that patients on dolutegravir gained an average of 1.78 kg in 12 months, compared to those on efavirenz.
A study found that long-acting injectable ART suppressed HIV in people with unstable housing, mental illnesses, and substance use disorders. The treatment improved outcomes in underserved patients, overcoming daily treatment barriers such as housing insecurity and untreated mental illnesses.
The DELIVER study found that the vaginal dapivirine ring posed no safety concerns when used in the third trimester of pregnancy. The study enrolled women at different stages of gestation and reported similar pregnancy outcomes between those using the ring and a placebo.
A Rutgers study found that older people living with HIV/AIDS face unmet mental health needs and are more likely to experience PTSD, substance dependence, and suicidal thoughts. Resilience may play a crucial role in increasing adherence to antiretroviral therapy, which is essential to ending the AIDS epidemic.
Research reveals that commonly used antiretroviral drugs TAF and TDF directly impact mitochondria's energy production in immune cells. The study suggests a larger energy reduction when combined with other antiretrovirals, sparking concerns about potential long-term effects on human cells.
A new study finds epigenetic aging is associated with aberrant neural oscillatory dynamics serving visuospatial processing in people with HIV. Participants showed accelerated biological age and different brain activity patterns compared to controls, suggesting a link between biological aging and neural function in PWH.
Researchers found that Covid vaccines effectively protect HIV-positive individuals, particularly after a third booster shot. The study also revealed a surprisingly strong cellular immune response in HIV-positive people, similar to those in healthy individuals.
Research in Zambia suggests children infected with HIV are more likely to struggle with cognitive and mental health issues despite well-controlled disease. Early intervention through better nutrition and antiretroviral therapies may improve neurological function.
A recent study published in The Lancet HIV found that individuals with viral suppression through antiretroviral therapy (ART) medications can live longer and experience less disability compared to those with unsuppressed HIV. This research highlights the critical importance of maintaining support for HIV treatment programs to ensure op...
A study found that dolutegravir-based antiretroviral therapy (ART) had a high probability of maternal viral suppression at delivery, outperforming commonly used ART regimens. The researchers also observed no significant differences in adverse birth outcomes between dolutegravir and other regimens.
A study led by Harvard T.H. Chan School of Public Health researchers found that dolutegravir-based regimens are more effective in treating HIV-1 during pregnancy than other commonly used ART regimens. The study showed high viral suppression rates for pregnant people taking dolutegravir, with no observed differences in adverse birth out...